ArticleClinical case reports2026
Docetaxel-Induced Serositis Mimicking Malignant Pleural Effusion.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pleural effusions are common in patients with cancer. Although their development may signal progressive malignant disease, drug-induced effusions are a rare and often overlooked cause of exudative pleural effusions. We describe a 50-year-old woman with recurrent granulosa cell tumor of the ovary who developed bilateral pleural and pericardial effusions after 10 cycles of docetaxel and bevacizumab. Imaging showed stable pelvic disease without thoracic metastases. Pleural fluid analysis revealed exudates with negative cytology and cultures. Pleuroscopy demonstrated normal pleura, and biopsies confirmed reactive mesothelial hyperplasia without malignancy. Bilateral indwelling pleural catheters were placed. After discontinuation of docetaxel, effusions resolved, and indwelling pleural catheters were removed. Docetaxel causes fluid retention, typically generalized, but isolated serositis is uncommon. In our case, the temporal association with docetaxel, absence of malignant pleural involvement, and resolution after drug cessation support a diagnosis of docetaxel-induced serositis. This highlights the importance of considering non-malignant etiologies in patients with cancer with new effusions. Further multidisciplinary evaluation in these cases is paramount. Drug-induced serositis should be considered in patients receiving docetaxel who develop pleural effusions, particularly when imaging shows stable disease and cytology is negative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.